Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra Investments. In this article, we will ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, a move investors said eases some concerns ...

Although Mounjaro and Zepbound have been headlining Lilly’s financial reports in recent years, the company’s roster of ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly & Co. said its Type-2 Diabetes drug Mounjaro and weight-loss/diabetes medicine Zepbound drove a 45% increase in fourth-quarter revenue to $13.53 billion.

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro, didn't grow as fast as it anticipated in the fourth quarter.

Eli Lilly reported mixed fourth-quarter results on Thursday, surpassing earnings expectations but falling short of sales projections, even as demand for its flagship weight loss drug Zepbound and ...

Eli Lilly, the world’s biggest drugmaker by market value, reported higher-than-expected quarterly profit and issued a bullish earnings forecast. Sales of weight-loss drug Zepbound and diabetes drug ...